Results
1 -
10 of
18Tyrosine Kinase Inhibitors and Neurodegenerative Disorders, Inflammation, Aging, and Oxidative Stress The c-Abl inhibitor in Parkinson disease, Neurological Sciences Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms, Impact of Genetic Targets on Cancer Therapy Bcr-Abl Kinase Inhibitors, Cancer Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs, Chemotherapy for Leukemia BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia, Annals of Hematology Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, Cancer Chemotherapy and Pharmacology